05.04.26 BY ALEXANDRE STIPANOVICH
Now that ibogaine and methylone join MDMA and psilocybin as potential treatments for PTSD, let's try to understand the pharmacology of how each of these compounds accesses and reprocesses trauma. MDMA, ibogaine, psilocybin, and methylone are four pharmacologically distinct compounds which produce durable reductions in PTSD symptoms, though for ibogaine and methylone the clinical evidence remains early stage. None work like antidepressants. None require daily dosing. None do the same thing at the receptor level. Yet they converge on a common outcome: the reprocessing of traumatic memory. Let's start with ibogaine.
Ibogaine is not a classical psychedelic. It does not bind 5-HT2A receptors with meaningful affinity. Its altered state comes from a different pharmacological address entirely: NMDA receptor antagonism, sigma-2 receptor agonism, and kappa opioid receptor engagement. This combination is what produces the experience ibogaine is known for, oneirogenic, introspective, autobiographical. People describe a structured life review: specific memories, often traumatic, replaying with unusual emotional distance (Alper, 2001). The traumatic content surfaces, but the emotional overwhelm is buffered.
How can the pharmacology help us understand this phenomenon? NMDA blockade disrupts thalamic gating of sensory information, producing dissociation. Kappa agonism shifts dopaminergic tone in ways that alter perception and suppress the reward signal (Glick et al., 1997). Sigma-2 engagement adds a further modulatory layer whose contribution to the subjective experience is still being characterised. Together, these actions create the conditions for what ibogaine does that other psychedelics do not: it reaches traumatic memory autonomously, uninvited, without the patient having to consciously direct attention toward it.
When ibogaine enters the body, the liver converts a portion of it into noribogaine via cytochrome P450 2D6 demethylation. Noribogaine is not a departure from ibogaine's pharmacology. It largely recapitulates it, retaining NMDA antagonism, kappa opioid agonism, and sigma receptor engagement, while adding one major new element: potent serotonin transporter blockade, with an IC50 of approximately 0.18 microM, roughly twenty times more potent than ibogaine itself at blocking serotonin reuptake (Baumann et al., 2001). The two compounds are therefore active simultaneously during the acute experience, with noribogaine extending and serotonergically amplifying a pharmacological profile ibogaine had already initiated.
This matters because neither noribogaine nor ibogaine are direct 5-HT2A agonists: they produce altered states through a different pharmacological route than classical psychedelics like psilocybin or LSD (Ali S. et al., 2025). By raising synaptic serotonin levels, noribogaine could indirectly activate 5-HT2A receptors simply by flooding the synapse with endogenous ligand, but the primary mechanism of action is distinct.
“The experience ibogaine creates is not the ego dissolution of classical psychedelics. It is oneirogenic (dream-like), introspective, autobiographical.”
Beyond SERT, noribogaine shows biased agonism at the kappa receptor: it activates the G protein pathway at about 75% the efficacy of dynorphin, while suppressing beta-arrestin recruitment to just 12% efficacy. It drives one intracellular signal while nearly silencing the other, producing a different net effect than a simple agonist or antagonist would (Maillet E.L. et al., 2015).
What makes the combined experience mechanistically unusual is duration. The altered state can persist for eight to twenty-four hours, far longer than receptor occupancy alone would predict. One proposed mechanism involves glial cell line-derived neurotrophic factor, or GDNF.
A single therapeutic dose of ibogaine increases GDNF expression in the ventral tegmental area within twenty-four hours (He D.Y. et al., 2005). GDNF then binds its receptor, RET, on dopamine neurons in that same region and triggers an autocrine loop: GDNF stimulates its own continued synthesis and release, sustaining altered dopaminergic tone long after the drug has cleared (He D.Y. et al., 2006). This mechanism was characterised in addiction models, specifically alcohol use disorder. Whether it contributes to PTSD symptom reduction specifically is not established. The evidence is indirect, the clinical translation is plausible but remains an open question.
What is reasonably supported is this: GDNF signaling promotes dopamine neuron survival, synaptic growth, and long-term plasticity in reward and stress circuits. If it does contribute to ibogaine's effects in trauma, it would represent a second therapeutic layer operating after the acute experience closes, a neuroplastic reorganisation of circuits dysregulated by chronic trauma.
The working hypothesis for the therapeutic sequence is: ibogaine's polypharmacology opens dissociated access to traumatic memories during the acute experience; memories surface with emotional distance and become available for reconsolidation; post-acute GDNF-driven plasticity may then encode durable circuit-level changes, though this final step remains to be confirmed in PTSD models.
Ibogaine reaches the traumatic memory autonomously, through pharmacological dissociation. The patient does not choose to approach it. The drug brings the memory forward.
In Part 2, we examine how MDMA approaches the same problem from the opposite direction: not by forcing memories to surface, but by creating the conditions in which a patient can choose to face them.
References
- Baumann MH et al. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther. 2001;297:531–539.
- Ali S, Tian X, Cunningham KA, Zhou J. Old Dog, New Tricks: Ibogaine and Its Analogs as Potential Neurotherapeutics. J Med Chem. 2025;68(18):18744–18751.
- Maillet EL et al. Noribogaine is a G-protein biased κ-opioid receptor agonist. Neuropharmacology. 2015;99:675–688.
- Alper KR. Ibogaine: A review. The Alkaloids: Chemistry and Biology. 2001;56:1–38.
- Glick SD, Maisonneuve IM, Pearl SM. Evidence for roles of κ-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res. 1997;749(2):340–343.
- He DY et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci. 2005;25(3):619–628.
- He DY, Ron D. Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB J. 2006;20:2420–2422.
